Key Points
- Chemed EVP Spencer Lee sold 920 shares at an average price of $537.17, totaling about $494,196. After the sale, he owned 13,931 shares, a 6.19% reduction in his position.
- Chemed reported quarterly earnings of $6.75 per share, beating estimates of $6.44, and revenue of $690.94 million, up 10.6% year over year.
- The company raised its quarterly dividend from $0.60 to $0.70 per share. Analysts’ consensus rating was “Hold,” with an average price target of $603.
Chemed Corporation (NYSE:CHE - Get Free Report) EVP Spencer Lee sold 920 shares of the firm's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $537.17, for a total transaction of $494,196.40. Following the sale, the executive vice president owned 13,931 shares of the company's stock, valued at approximately $7,483,315.27. This represents a 6.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Chemed Stock Performance
Shares of CHE stock opened at $534.10 on Wednesday. The company has a market capitalization of $6.95 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 2.06 and a beta of 0.50. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.08 and a current ratio of 1.11. The company has a 50-day simple moving average of $514.53 and a 200 day simple moving average of $463.84. Chemed Corporation has a 52 week low of $365.20 and a 52 week high of $562.24.
Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $6.75 EPS for the quarter, beating analysts' consensus estimates of $6.44 by $0.31. The business had revenue of $690.94 million for the quarter, compared to analyst estimates of $685.04 million. Chemed had a net margin of 10.61% and a return on equity of 35.18%. Chemed's quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.27 EPS. On average, sell-side analysts predict that Chemed Corporation will post 24.05 earnings per share for the current year.
Chemed Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were issued a dividend of $0.70 per share. This is a boost from Chemed's previous quarterly dividend of $0.60. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Monday, August 17th. Chemed's dividend payout ratio is presently 13.40%.
Analyst Ratings Changes
CHE has been the topic of a number of recent research reports. UBS Group increased their target price on Chemed from $650.00 to $675.00 and gave the stock a "buy" rating in a research note on Thursday, October 29th. Weiss Ratings raised Chemed from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th. Royal Bank Of Canada boosted their price target on Chemed from $548.00 to $585.00 and gave the company a "sector perform" rating in a research note on Thursday, October 29th. Wall Street Zen raised Chemed from a "buy" rating to a "strong-buy" rating in a report on Saturday, October 10th. Finally, Oppenheimer upped their price objective on Chemed from $590.00 to $625.00 and gave the company an "outperform" rating in a report on Thursday, October 29th. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $603.00.
Read Our Latest Research Report on Chemed
Institutional Trading of Chemed
A number of institutional investors have recently bought and sold shares of the business. Ethic Inc. grew its position in shares of Chemed by 20.0% during the 3rd quarter. Ethic Inc. now owns 1,343 shares of the company's stock worth $678,000 after purchasing an additional 224 shares in the last quarter. Palisade Asset Management LLC acquired a new stake in shares of Chemed in the third quarter valued at approximately $269,000. Parallel Advisors LLC raised its position in shares of Chemed by 10.8% in the third quarter. Parallel Advisors LLC now owns 596 shares of the company's stock valued at $301,000 after buying an additional 58 shares in the last quarter. United Advisor Group LLC raised its position in shares of Chemed by 7.0% in the third quarter. United Advisor Group LLC now owns 1,554 shares of the company's stock valued at $785,000 after buying an additional 102 shares in the last quarter. Finally, Kestra Advisory Services LLC boosted its stake in shares of Chemed by 115.9% in the third quarter. Kestra Advisory Services LLC now owns 3,273 shares of the company's stock valued at $1,653,000 after buying an additional 1,757 shares during the period. Institutional investors own 95.85% of the company's stock.
Chemed Company Profile
(
Get Free Report)
Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.
VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients' homes, hospice inpatient units, hospitals, nursing facilities and other care settings.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
